PsyBio Therapeutics (STU:PSYB) Selling, General, & Admin. Expense: €2.30 Mil (TTM As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is PsyBio Therapeutics Selling, General, & Admin. Expense?

PsyBio Therapeutics STU:PSYB Selling, General, & Admin. Expense is €2.30 Mil as of Jun. 2023.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. PsyBio Therapeutics's selling, general, & admin. expense for the three months ended in Jun. 2023 was €0.10 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Jun. 2023 was €2.30 Mil.


PsyBio Therapeutics  (STU:PSYB) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


PsyBio Therapeutics Selling, General, & Admin. Expense Related Terms


PsyBio Therapeutics Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for PsyBio Therapeutics's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PsyBio Therapeutics Selling, General, & Admin. Expense Chart

PsyBio Therapeutics Annual Data
Trend Dec21 Dec22
Selling, General, & Admin. Expense
7.88 3.73

PsyBio Therapeutics Quarterly Data
Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.08 0.85 0.68 0.67 0.10

STU:PSYB vs VRTX, REGN, SGEN: Selling, General, & Admin. Expense Comparison

For the Biotechnology subindustry, PsyBio Therapeutics's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PsyBio Therapeutics Selling, General, & Admin. Expense vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PsyBio Therapeutics's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where PsyBio Therapeutics's Selling, General, & Admin. Expense falls into.



PsyBio Therapeutics Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of €2.30 Mil mean?
PsyBio Therapeutics (STU:PSYB) has a Selling, General, & Admin. Expense of €2.30 Mil as of Jun. 2023. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on PsyBio Therapeutics and its competitors.
Is PsyBio Therapeutics' Selling, General, & Admin. Expense too high?
PsyBio Therapeutics' current Selling, General, & Admin. Expense is €2.30 Mil.
How does PsyBio Therapeutics' Selling, General, & Admin. Expense compare to VRTX and REGN?
PsyBio Therapeutics' Selling, General, & Admin. Expense of €2.30 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on PsyBio Therapeutics and its competitors. PsyBio Therapeutics's current Selling, General, & Admin. Expense is €2.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PsyBio Therapeutics stock overvalued right now?
PsyBio Therapeutics (STU:PSYB) has a current Selling, General, & Admin. Expense of €2.30 Mil. The current Selling, General, & Admin. Expense is €2.30 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For PsyBio Therapeutics (STU:PSYB), the current Selling, General, & Admin. Expense is €2.30 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PsyBio Therapeutics Business Description

Address 1624 Washington Street, Denver, CO, USA, 80203
PsyBio Therapeutics Corp is a biotechnology company. The company is engaged in the development of drugs intended for the treatment of mental illness and neurological disorders.